Answers are grounded in this paper and cite their sources.
Mepolizumab therapy reduces exacerbations and improves AQLQ scores in patients with refractory eosinophilic asthma. The results of our study suggest that eosinophils have a role as important effector cells in the pathogenesis of severe exacerbations of asthma in this patient population. (Current Controlled Trials number, ISRCTN75169762.)
No takes yet. Share an insight, caveat, or question.
Haldar et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: